Targets

MDM2

5 articles

Medicinal ChemistryACS Medicinal Chemistry Letters

Etrasimod-derived cyclopenta[b]indoles emerge as a new scaffold for dual MDM2/MDM4 inhibition and p53 activation

  • Virtual screening against both MDM2 and MDM4 flagged the approved drug etrasimod as a dual binder.
  • Structure-guided changes to its cyclopentyl group gave six cyclopenta[b]indole analogues aimed at the shared hydrophobic Leu-26 pocket.
  • The 3,4-dichlorophenyl analogue was strongest, binding both proteins in the low-micromolar range, and in SJSA-1 cells it raised p53 and apoptosis markers.
PointsBased on the abstract

A fair starting point for a repurposed hit, but was the parent's S1P receptor activity engineered out? That off-target liability would follow the scaffold. SJSA-1 is MDM2-amplified and p53 wild-type, so a p53-null counter-screen should come first, along with a nutlin-class reference to show how large the potency gap really is.

Computational & AIchemRxiv

DEL-Flow: DEL selection data steer a flow-matching generator to MDM2–p53 macrocyclic peptides with confirmed activity

  • Two rounds of DNA-encoded library selection on symmetric then asymmetric macrocyclic peptides pointed to an enriched half-scaffold, which was kept fixed.
  • The selection signals, generated conformations and MDM2 pocket poses trained a pocket-conditioned SE(3)-equivariant flow-matching model that varies side chains around the macrocyclic core.
  • From two templates, 40 candidates were generated; two were prioritized and resynthesized off DNA, and both inhibited MDM2–p53 in fluorescence polarization, in the micromolar IC50 range.
  • The authors conclude that DEL signals plus pocket geometry can guide generation of macrocycles not present in the library.
PointsBased on the abstract

Using DEL enrichment as the training prior rather than scarce IC50 data is the clever part, and it answers the usual data-scarcity problem for macrocycles. But micromolar hits from 2 of 40 candidates is a modest return when the DEL itself already produced enriched binders; the question is how it compares with simply picking more library members. Check selectivity against MDM4 and the cell activity next.

Medicinal ChemistryOrganic Letters

N-terminal mercaptoproline capping with a cysteine cross-link stabilizes peptide helices to engage MDM2 inside cancer cells

  • Short peptides seldom keep a stable helix, hampering intracellular protein–protein interaction targeting; the authors cap the N-terminus with 4-mercaptoproline.
  • A covalent bridge to an internal cysteine preorganizes the backbone and encourages helix propagation.
  • Adjusting residue stereochemistry and linker composition improved helicity, uptake, protease stability and MDM2 binding, with reduced cancer cell viability and migration.
PointsBased on the abstract

All-hydrocarbon staples tend to add greasy bulk that hurts solubility; here the N-terminal cap does double duty as helix nucleator and cross-link anchor, which is neater. For an MDM2 p53-mimetic I'd still want the thiol bridge's stability in cytosol and resistance to reduction checked, but it's a cheaper handle than another staple screen.

Computational & AIChemMedChem

Residue-level energy view of TP53-MDM2/MDMX inhibitors favors stabilized peptides

  • Unrestricted molecular dynamics and QM/MM calculations were used to break down inhibitor binding to MDM2 and MDMX into per-residue electrostatic and van der Waals contributions.
  • The set covered all clinical-stage inhibitors with high-resolution structures; this is a computational study without new experiments.
  • Binding proved weak and dispersion-driven, with water solvation important; stabilized peptides showed a more favorable interaction pattern than small organic molecules.
PointsBased on the abstract

Per-residue decomposition is useful for seeing where a ligand loses to repulsion, but a few MD runs with a fixed force field won't give you affinities, and with no experiments the stapled-peptide advantage is an interpretation, not a result. Peptides simply have more contacts to sum. I'd mine it for hot-spot and clash maps to guide small-molecule design, not as evidence that peptides win.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Hsc70-Recruiting Degraders Exploit Chaperone-Mediated Autophagy for Targeted Protein Degradation

  • Researchers developed Hsc70-Mediated Targeting Chimeras (Hsc70TACs), bifunctional small molecules that link an Hsc70-binding ligand to a ligand for a protein of interest, directing target degradation through chaperone-mediated autophagy rather than the ubiquitin-proteasome pathway used by PROTACs.
  • The approach is proposed to extend the range of degradable targets, including certain cytosolic and cell-membrane proteins, and to offer an alternative route that may help address resistance risks associated with proteasome-dependent degraders.
  • Degradation activity was demonstrated across multiple protein classes, including the transcriptional regulator BRD4, the regulatory protein MDM2, and the cell-membrane immune checkpoint protein PD-L1, across diverse cellular contexts.
  • A lead BRD4-directed compound, B-2, showed favorable pharmacokinetic behavior and produced robust BRD4 degradation in vivo, supporting continued development of the Hsc70TAC modality.
PointsBased on the abstract

A degradation route that bypasses CRBN/VHL entirely is worth my attention regardless of target — CMA recruitment sidesteps the ubiquitin-proteasome toolbox, so it should be orthogonal to the resistance mechanisms (neosubstrate mutation, E3 downregulation) that kill PROTAC leads in the clinic. PD-L1 is the result I'd chase: pulling a membrane protein through chaperone-mediated autophagy via LAMP2A translocation is something UPS-based PROTACs structurally can't do. My skepticism sits with the Hsc70 arm — KFERQ-motif engagement is promiscuous by design, so selectivity and off-target chaperone-client disruption need real scrutiny before I trust the SAR. B-2's in vivo PK and clean BRD4 knockdown at least de-risks synthesis/linker chemistry enough to treat this as a platform, not just a proof of concept.